AURA Stock Analysis: Buy, Sell, or Hold?
AURA - Aura Biosciences, Inc. Common Stock
$7.74
1.01 (15.01%)
▲
5d:
+12.83%
30d:
+12.17%
90d:
+15.52%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When AURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AURA is currently trading at $7.74, which is considered extended relative to its 30-day fair value range of $6.37 to $7.26.
Technical Outlook: Technically, AURA is in a uptrend. The price is approaching resistance at $7.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 15.0% recently.
Market Sentiment: AURA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.80 (+142.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AURA is in a uptrend. The price is approaching resistance at $7.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 15.0% recently.
Market Sentiment: AURA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.80 (+142.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.37 -
$7.26
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+6.6% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+15.0%)
- BULLISH: Trading 142.9% below Wall St target ($18.80)
Trading Range Analysis
30-Day Trading Range
$6.37 -
$7.26
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.16
Resistance Level
$7.75
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.64
Wall Street Target
$18.80
(+142.9%)
Share & Embed Analysis
Last updated: July 05, 2026 5:48 PM ET
Data refreshes hourly during market hours. Next update: 6:48 PM
Data refreshes hourly during market hours. Next update: 6:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AURA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Conor Kilroy
SELL
11738 shares
2026-04-16
Amy Elazzouzi
SELL
8549 shares
2026-02-17
Conor Kilroy
SELL
12079 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
